Calixar Raises €1 Million
News Feb 25, 2015
Calixar has announced the completion of its second round of financing with its historical investors - Siparex, Veymont Participations, INPG Entreprise SA, and regional business angels (Health-Angels Rhône-Alpes, Savoie Angels and Grenoble Angels).
Moreover, Bpifrance (French public investment bank) and the Banque Populaire supplemented this funding through repayable advance and specific credit (Innov & Plus) supported by the European Union.
The new financing will enable Calixar to confirm its excellent results, especially on the development of new Influenza vaccines and high affinity antibodies to GPCRs; they will be available for partnership with the pharmaceutical industry by the second semester 2015.
Calixar unique approach allows to preserve the native state of membrane proteins - 70% of therapeutic targets - involved in numerous pathologies. The company currently owns 5 patents.
“We are very proud of the continued confidence of our historical investors and financial partners. These funds will enable us to accelerate our internal research programs while continuing to offer our know-how and technologies to support our clients’ discovery programs in Europe, the United States and Japan”, declared Emmanuel Dejean, President & CEO of Calixar.
“Considering the good results obtained with global pharmaceuticals leaders as well as the recent encouraging breakthroughs on internal programs, we have decided to renew our support to Calixar to achieve this new stage of development” explained Guilhem De Vregille, Associate Director of Siparex Venture Capital.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Antigen Study Shows Promise for a Respiratory Syncytial Virus VaccineNews
Medical researchers have been trying to develop a vaccine for respiratory syncytial virus (RSV) for more than 50 years, without success. New findings however, point to a promising route for designing an effective vaccine. Researchers determined the atomic structure of RSV G (major viral surface protein) and identified two sites on it that are targeted by protective antibodies effective against a broad range of RSV strains.READ MORE
The Enemy Within: Gut Bacteria Drive Autoimmune DiseaseNews
Bacteria found in the small intestines of mice and humans can travel to other organs and trigger an autoimmune response, according to a new study. The researchers also found that the autoimmune reaction can be suppressed with an antibiotic or vaccine designed to target the bacteria.READ MORE